Podcasts

In this podcast, Neurology Learning Network's Stroke & Vascular Section Editor Amrou Sarraj, MD, reviews major intravenous thrombolysis trial data that emerged in 2020, including data for extending thrombolysis beyond the traditional 4.5-hour window, data from the EXTEND-IA TNK Part 2 Randomized Clinical Trial, and more. A full transcript is provided.
In Episode 1, Rachel Marie E. Salas, MD, interviews Nancy Collop, MD, and Charlene Gamaldo, MD, about the impact of COVID-19 on their sleep centers at Emory University and Johns Hopkins University, respectively, from the start of the pandemic until now. A full transcript is provided.
In this podcast, Joohi Jimenez-Shahed, MD, discusses the findings of the study, “Safety, Tolerability, and Pharmacodynamic Profile of DNL201 at dose levels demonstrating LRRK2 inhibition in Parkinson's Disease Patients with and without LRRK2 mutations,” which was presented at the International Parkinson and Movement Disorder Society Virtual Congress.
In this podcast, Neurology Learning Network's Stroke & Vascular Section Editor Amrou Sarraj, MD, gives a snapshot of key stroke prevention trial data that were unveiled in 2020—the THALES trial, the RIVER trial, and the Treat Stroke to Target Trial. A full transcript is provided.
In this podcast, Neurology Learning Network's Sleep Medicine Section Editor Joseph Diamond, MD, discusses new drug approvals, phase 3 clinical trial data, "COVID-somnia," and more developments from 2020. A full transcript is provided.
In this podcast, Dr Coyle discusses the "final word" on strategies to promote remyelination in multiple sclerosis from the ECTRIMS/ACTRIMS MSVirtual2020 meeting.
In this podcast, Dr Coyle discusses the "final word" on myelin oligodendrocyte glycoprotein-mediated disease in multiple sclerosis from the ECTRIMS/ACTRIMS MSVirtual2020 meeting.
Alastair Noyce, MD, discusses his recent study, which found that patients with Parkinson disease have likely had less access to medication during the COVID-19 pandemic, which in turn may impact patients' symptomatic control.
In this podcast, Dr Coyle discusses the "final word" on neuromyelitis optica spectrum disorder in multiple sclerosis from the ECTRIMS/ACTRIMS MSVirtual2020 meeting.
In this podcast, Dr Markman discusses promising findings from a large phase 3 trial comparing subcutaneous tanezumab vs tramadol and placebo among patients with chronic low back pain and history of inadequate response or intolerance to standard-of-care analgesics.